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All aspects of lung cancer care will benefit from the development of accurate molecular biomarkers. Those that can predict the risk of developing lung cancer will help in the 
selection of subjects for lung cancer screening. Those that can identify the presence of early-
stage lung cancer will help in the evaluation of indeterminate lung nodules. Those capable of 
prognosticating outcome will assist in planning the aggressiveness of treatment. Those capa-
ble of predicting the response to systemic therapies will help to individualize their selection.
Over the past decade, molecular biomarker discovery has been dominated by studies 
assessing the genome, transcriptome, and proteome. Alterations of individual molecules, 
or patterns of multiple alterations, have been presented as potential biomarkers. To date, 
with the exception of epidermal growth factor receptor mutation testing1 and echinoderm 
microtubule-associated protein-like 4 anaplastic lymphoma kinase identification,2 none of 
the molecular biomarkers have been developed to the point of technical and clinical valida-
tion, and/or proven clinical utility.
Metabolomics is a source of potential molecular biomarkers, which has been relatively 
under-represented in the literature. Metabolomics refers to an assessment of the products of cel-
lular metabolism. In a systems biology approach, the metabolome can be considered the prod-
uct of the interaction between the genome, transcriptome, and proteome with an individual’s 
physiologic status. Traditionally, metabolomics involves the study of nonvolatile endogenous 
small molecule metabolites such as amino acids, carbohydrates, and lipids, in tissue, blood, or 
urine. Nonvolatile metabolite profiling can be performed as an overview of the metabolome, or 
as a targeted look at a metabolic pathway, or a specific metabolite. To date, published studies 
of nonvolatile metabolite profiling in lung cancer have been small, pilot studies. Differences in 
metabolite signatures between tumor and adjacent control tissue,3 as well as serum and urine 
of lung cancer patients compared with healthy controls,4–6 have been reported.
In addition to nonvolatile metabolites, volatile organic compounds (VOCs) can be 
produced or degraded as part of cellular metabolism and the handling of oxidative stresses. 
They can be identified in the headspace gas of tissues,7 blood,8 urine,9 and in the exhaled 
breath.10 They can be evaluated for differences in a specific compound, class of compounds, 
or as a general overview of the spectrum of VOCs present in the biospecimen. VOC profiles 
in lung cancer have been analyzed with gas chromatography mass spectrometry (GC-MS), 
other spectrometry technologies, and cross-responsive chemical sensor matrices. GC-MS 
is capable of identifying selected VOCs and their concentrations, whereas the signal from 
the sensor technologies reflects the broad mixture of VOCs within the specimen without 
identifying the specific components of the mixture. These studies have been relatively small 
and highly variable in their methods, but have shown promising accuracy.
In this issue of the Journal Thoracic Oncology, Pelid et al. report on the development 
of a breath VOC biomarker identified by a cross-responsive sensor matrix using a 
combination of a gold nanoparticle sensor and a single-walled carbon nanotube sensor, 
as well as evaluation of selected breath samples with GC-MS. They sampled alveolar 
breath from 53 lung cancer subjects with early- and late-stage disease as well as 19 control 
subjects with benign lung nodules. The groups were well matched for smoking histories, 
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but differed in age and size of the primary nodule/mass. The 
sensor signal distinguished between the two groups with an 
accuracy of 88%. The influence of clinical variables on the 
model’s accuracy was not studied, and the model was not 
validated in a separate cohort of subjects. The sensor signal 
was also capable of accurately characterizing lung cancer 
histology and stage. This study adds to the growing literature 
in this area, suggesting that breath VOC biomarkers have the 
potential to be developed into clinically useful diagnostic tests. 
In addition, the results support the premise that a metabolic-
based biomarker can be used to help characterize the nature 
of the cancer.
Future breath VOC biomarker development will benefit 
from advances in many areas. Novel gas analysis technologies 
will help to define more accurately the unique components 
of the breath VOC mixture, allowing study of their origin, 
improvement in our knowledge of lung cancer metabolics, and 
refinement of point-of-care sensor systems. Standardization 
of breath sampling techniques will lead to greater reproduc-
ibility of the results of breath testing. Lung cancer phenotyp-
ing will promote the development of breath VOC signatures 
of more refined populations. In time, the promise shown in 
early studies could translate into technically and clinically 
validated, inexpensive, noninvasive molecular biomarkers that 
are accurate enough to improve patient care.
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